Manufacturing Medicine’s Post

The emergence of CAR T cell therapy has shown remarkable success in treating hematological malignancies, yet challenges like toxicities and limited efficacy in solid tumors persist. In response, innovative engineering strategies have led to the development of CAR NK cells, offering promising next-generation immunotherapies. A recent review compares CAR T and CAR NK cell therapies, highlighting their unique features, engineering advancements, and ongoing challenges. #Immunotherapy #CARTcells #CARNKcells #CancerResearch

Great news here

2024 anticipates 17 approvals, Pharma's relentless M&A interest in CGT? Here's the NEW wave of cell therapies 👇 The momentum is undeniable as CGT showcases robust R&D progress, post JPM optimism with promising signs of commercial traction to come. Kudos to Amy Adelman House (CC' Courtney Rice) for a comprehensive post on Syncona Limited CGT overview. One standout slide caught my eye, as seen below, highlighting our dynamic landscape and future. 🏄♂️ I certainly agree that CAR-Treg and Macrophages will be LEADING this new wave of cell therapies, perhaps a third area will surprise us... 𝘞𝘩𝘢𝘵 𝘢𝘳𝘦 𝘺𝘰𝘶𝘳 𝘱𝘳𝘦𝘥𝘪𝘤𝘵𝘪𝘰𝘯𝘴 𝘧𝘰𝘳 𝘊𝘎𝘛 𝘪𝘯 2024? #celltherapy #genetherapy #oncology #CGTweekly

New research challenges the notion that the highest affinity always leads to the best outcome in CAR T cell therapy. A recent article highlights that weaker affinity CAR T cells demonstrated comparable killing rates against neoplastic cells expressing high levels of CAIX, while exhibiting enhanced migration potential and comparable inhibition of tumor growth. This highlights that in CAR T cell therapy, superior performance is not solely determined by the highest affinity. #CARTcelltherapy #immunotherapy #cancerresearch

🔬 Considering investing in CAR T-cell therapy? Here's why it's a smart move: 1️⃣ High efficacy: CAR T treatments show exceptional effectiveness, especially in blood cancers. 2️⃣ Diverse applications: CAR T therapy is now expanding into solid tumors, which widens market potential. 3️⃣ Personalized approach: Tailored treatments based on individual patient profiles enhance efficacy. 4️⃣ Market growth: The CAR T market is projected to experience substantial growth in the coming years, offering promising returns. 5️⃣ Continuous innovation: Ongoing R&D efforts ensure competitiveness and drive future growth. 6️⃣ Addressing critical needs: CAR T therapy tackles unmet medical needs, making it both financially rewarding and socially impactful. We have created iTANK, a patented genetic engineering method, for arming of existing CAR T-cell therapies for aggressive and recurrent solid cancers. Our CAR T-cell therapies have proven successful in preclinical studies against challenging solid tumors. Find out more about Elicera Therapeutics and get in touch!

Important read 👇🏽

PICI Center Directors Crystal Mackall, MD, and Carl June, MD, and PICI CSO John Connolly, PhD, collaborated with ISCT, International Society for Cell & Gene Therapy to address a crucial concern raised by the FDA regarding T-cell malignancy in patients treated with BCMA- or CD19-directed autologous CAR T-cell immunotherapy. “Unanswered questions following reports of secondary malignancies after CAR T-cell therapy," published in Nature Medicine, explores the complexities surrounding the potential risks while emphasizing the continued importance of CAR T-cell therapies. PICI and the consortia agree that while these reports warrant investigation, existing follow-up data suggest a relatively low risk compared to other cancer treatments. The commentary emphasizes that the continued benefits of CAR T-cell therapies outweigh the potential risks for most patients. However, vigilance, monitoring, and ongoing research for safety and efficacy are crucial. Read the full paper: https://lnkd.in/giRZ7_xz #CellTherapy #GeneTherapy #MedicalResearch #PICINetwork

Glioblastoma stands as one of the most formidable challenges in solid tumor therapeutics, with current CAR-T approaches encountering limitations in achieving significant efficacy. However, the potential lies in harnessing T cells' tissue traversal capabilities and engineering them to penetrate the blood-brain barrier (BBB). This advancement could represent a transformative breakthrough, particularly for glioblastoma patients, offering a promising avenue for enhanced treatment strategies. https://lnkd.in/gz2tsMSt

A landmark study for the fields of #celltherapy and #NaturalKiller cells. The CD19 CAR-NK cells compared well to CAR-T cells in terms of efficacy in NHL, CLL, & DLBCL on an ITT basis, but 0/37 recipients developed neurotoxicity, and only 1/37 developed cytokine release syndrome and that was Grade 1 (mild). Both side effects are common and sometimes severe with CAR-T cell therapy often necessitating hospitalization and costly management. This bodes well for an off-the-shelf therapy in terms of potential use outside specialist medical centers where CAR-T patients are frequently admitted to control side effects. Indeed, in the week FiercePharma published an excellent piece showing that the need for specialist care is limiting CAR-T uptake, CAR-NK may be part of the answer. In a true tour de force they authors also identified factors in the cord blood starting material that correlate with success, promising even better activity if CAR-NK products can be made only from optimally performing cord units.

New study identifies 2 key factors that impact the outcomes of #allogenic CD19 directed CAR NK cells. Cord blood units that were cryopreserved within 24 hours of collection and those with a low nucleated red blood cell content were associated with markedly better outcomes. #celltherapy #CARNKcells #CD19 #allogenic #Bcell #lymphoma #mdanderson